HCWB
HCW Biologics Inc.
There isn't enough reported data to score HCWB yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HCWB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
HCWB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HCWB PE Valuation
HCWB has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
HCWB Forward outlook
There aren't enough analyst estimates for HCWB to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
HCWB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2025 | -$148.80 | +$33.60 |
| Q4 2024 | -$184.80 | -$16.80 |
| Q3 2024 | -$240.00 | -$108.00 |
| Q2 2024 | -$249.60 | -$124.80 |
| Q1 2024 | -$182.40 | -$62.40 |
| Q4 2023 | -$168.00 | -$67.20 |
NVO has the stronger earnings trend. Trailing diluted EPS is down 182% for HCWB versus NVO up 4.9%.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
HCWB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $121.7K | +1758% |
| Q1 2026 | $6.5M | +128232% |
| Q4 2025 | $27K | -93% |
| Q3 2025 | $15.6K | -96% |
| Q2 2025 | $6.6K | -99% |
| Q1 2025 | $5.1K | -100% |
| Q4 2024 | $394.8K | -70% |
| Q3 2024 | $426.4K | -50% |
HCWB's revenue is growing: $121,730 last quarter, up 1758% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2601% | +50286 points |
| Q1 2026 | 50% | +38861 points |
| Q4 2025 | -16519% | -15719 points |
| Q3 2025 | -21095% | -20230 points |
| Q2 2025 | -52887% | -50441 points |
| Q1 2025 | -38811% | -38146 points |
| Q4 2024 | -800% | +13 points |
| Q3 2024 | -865% | -270 points |
HCWB's operating margin was −2601% last quarter, up 50286 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over HCWB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over HCWB on profitability, with a higher operating margin.
HCWB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4M | -$683.8K |
| Q1 2026 | -$1.6M | +$1.9M |
| Q4 2025 | -$3.4M | -$407.2K |
| Q3 2025 | -$3.2M | -$276.4K |
| Q2 2025 | -$3.3M | +$1.6M |
| Q1 2025 | -$3.5M | +$219.7K |
| Q4 2024 | -$2.9M | +$4.7M |
| Q3 2024 | -$3M | +$3.3M |
HCWB has burned cash in almost every quarter: −$12M over the past year, against −$13M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over HCWB on cash generation, producing positive trailing cash flow while its opponent burns cash.
HCWB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +280% | +978K shares |
| 1 year | +613% | +1.1M shares |
| 3 years | +788% | +1.2M shares |
| 5 years | +1014% | +1.2M shares |
HCWB has 1M diluted shares, up 613% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over HCWB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
HCWB Net Leverage
HCWB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
HCWB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.8 | Neutral |
| Stochastic | 0.6 | Oversold |
HCWB's weekly RSI is 37 (neutral) and its Stochastic is 1 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
HCWB PE vs Healthcare Sector
HCWB has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HCWB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.32 | 39% below |
| 20 week MA | $2.39 | 67% below |
| 50 week MA | $4.72 | 83% below |
| 100 week MA | $26.6 | 97% below |
| 200 week MA | $171.4 | 100% below |
HCWB is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over HCWB on trend strength, trading above more of its moving averages.
HCWB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $1,245.6 | $600.0 | -52% |
| 2022 | $600.0 | $472.8 | -21% |
| 2023 | $472.8 | $295.2 | -38% |
| 2024 | $295.2 | $100.8 | -66% |
| 2025 | $100.8 | $8.52 | -92% |
| 2026 YTD | $8.52 | $0.80 | -91% |
HCWB has finished every year since 2021 lower, and it's down 91% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over HCWB on returns for 2026, with the stronger performance.